Neisseria meningitidis group A, C, Y, W-135 polysaccharide–diphtheria toxoid conjugate (MenACWY-D)

This vaccine component is a conjugate antigen comprising the capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y, and W-135, each covalently linked to a diphtheria toxoid carrier protein[1][3]. The conjugation enhances immunogenicity by inducing robust, T cell–dependent antibody responses and immune memory, even in young children—a key advancement over earlier polysaccharide-only vaccines[3][4][5][6]. It is used for the prevention of invasive meningococcal disease, with Menactra and other MenACWY conjugate vaccines licensed globally. This molecule is not a single, discrete molecular “target,” but rather an immunogenic blend used to stimulate adaptive immunity against serious bacterial infections. Note: If structured for a drug target database, this complex would not normally be considered a canonical target but rather a vaccine antigen mixture, and no single gene or protein target applies. The terminology and data structure here follow conventions requested in the prompt, with full transparency regarding the unusual nature of this entry relative to standard drug targets.

Other names

MenACWY-DTetravalent meningococcal polysaccharide–diphtheria toxoid conjugateMeningococcal polysaccharide–protein conjugate vaccineMenactra (brand name)

Induces T cell–dependent immune response by presenting bacterial polysaccharide antigens on protein carrier (diphtheria toxoid), greatly improving immunogenicity and immunological memory compared to non-conjugated vaccines